Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Clin Exp Rheumatol. 2012 May-Jun;30(3 Suppl 72):S73-5. Epub 2012 Sep 27.

Refractory neuro-Behçet treated by tocilizumab: a case report.

Author information

  • 1Rheumaklinik und Institut für Physikalische Medizin und Rehabilitation, Kantonsspital Aarau AG, CH-5001Aarau, Switzerland. piotr.urbaniak@usz.ch


A patient with central nervous system involvement of Behçet's disease was refractory to conventional immunosuppressive therapy and showed secondary failure of the anti-TNF agent infliximab. This presented as a progressive weakness of the legs and reduction in walking distance. The cerebrospinal fluid showed signs of inflammation including a vastly elevated IL-6 concentration. Given this result, the anti-IL-6 receptor antibody tocilizumab was administered and a good improvement of inflammatory parameters and a satisfactory increase of the walking distance were achieved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Clinical and Experimental Rheumatology
    Loading ...
    Write to the Help Desk